

Special Issue

Immune Response after Vaccination against SARS-CoV-2 in Patients with Chronic Diseases

Message from the Guest Editor

This **Special Issue** aims to update the current knowledge and future directions of SARS-CoV-2 vaccination and management in patients with chronic medical conditions (patients with solid/hematological malignancies, those who have received organ transplants, patients on dialysis, those receiving immunosuppressive medications, elderly individuals, individuals with morbid obesity, and possibly other patient groups) **In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:**

- Immune response to SARS-CoV-2 vaccines in patients with chronic diseases.
- Vaccination strategy and vaccine classes (additional and booster vaccine shots, combination of vaccine classes).
- Efficacy of vaccination in patients with chronic medical conditions: laboratory and/or clinical evaluation.
- SARS-CoV-2 management of the immunocompromised beyond vaccination.
- Other related topics.

Guest Editor

Dr. Noa Berar Yanay

1. Head of Nephrology Department, Hillel Yaffe Medical Center, Hadera 38100, Israel
2. Rappaport Faculty of Medicine, Technion Israel, Haifa 32000, Israel

Deadline for manuscript submissions

closed (31 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/116293

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).